Article
Oncology
Donghao Xu, Yu Liu, Wentao Tang, Lingsha Xu, Tianyu Liu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Jisheng Li, Jiemin Zhao, Lechi Ye, Wenju Chang, Jianmin Xu
Summary: This study examined the treatment patterns of regorafenib in patients with advanced metastatic colorectal cancer in China. The results showed that both regorafenib monotherapy and combination therapy provided some relief for patients, with regorafenib plus anti-PD-1 antibodies showing better progression-free survival and regorafenib plus chemotherapy yielding the greatest benefit in overall survival. The study also found no significant difference in adverse events among the three groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Meng-Che Hsieh, Kun-Ming Rau, Shung-Eing Lin, Kuang-Wen Liu, Chong-Chi Chiu, Chih- Chen, Ling-Chiao Song, Hsin-Pao Chen
Summary: This observational study compared the efficacy of trifluridine/tipiracil (TAS-102) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC). The results showed that TAS-102 had better oncologic outcomes in terms of progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR) compared to REG. Combination therapy was associated with longer survival in both TAS-102 and REG groups. Further prospective trials are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Takeshi Kato, Toshihiro Kudo, Yoshinori Kagawa, Kohei Murata, Hirofumi Ota, Shingo Noura, Junichi Hasegawa, Hiroshi Tamagawa, Katsuya Ohta, Masakazu Ikenaga, Susumu Miyazaki, Takamichi Komori, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Chu Matsuda, Taroh Satoh, Tsunekazu Mizushima, Yuko Ohno, Hirofumi Yamamoto, Yuichiro Doki, Hidetoshi Eguchi
Summary: A prospective study found that a daily dose of 120 mg of Regorafenib showed significant efficacy and safety in the treatment of colorectal cancer, which may be beneficial to specific patient populations.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Ya-Ya Deng, Xin-Yue Zhang, Peng-Fei Zhu, Hong-Rui Lu, Qian Liu, Shuang-Yue Pan, Zhe-Ling Chen, Liu Yang
Summary: This study analyzed the data of patients with metastatic colorectal cancer who were treated with fruquintinib and regorafenib, and compared the efficacy and safety of the two drugs. The results showed that fruquintinib monotherapy had better disease control rate and objective remission rate in post-line therapy of metastatic colorectal cancer. Additionally, the combination of PD-1 immunotherapy further enhanced the effectiveness. Patients treated with regorafenib and then fruquintinib had significantly longer survival than those with the reverse treatment sequence. The adverse reactions of fruquintinib and regorafenib were similar.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Thomas B. Karasic, Timothy J. Brown, Charles Schneider, Ursina R. Teitelbaum, Kim A. Reiss, Tara C. Mitchell, Ryan C. Massa, Mark H. O'Hara, Lisa DiCicco, Luis Garcia-Marcano, Ravi K. Amaravadi, Peter J. O'Dwyer
Summary: The combination of regorafenib, HCQ, and entinostat showed poor tolerability and no significant therapeutic effect in patients with metastatic CRC.
Article
Oncology
Qi Zhang, Mifen Chen, Zhenghang Wang, Changsong Qi, Yanshuo Cao, Junyan Zhang, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, Jian Li
Summary: This ambispective observational cohort study evaluated the differences in efficacy and safety between regorafenib and fruquintinib in patients with refractory metastatic colorectal cancer (mCRC) in China. The study found that regorafenib and fruquintinib had similar efficacy in a real-world setting and their toxicity profiles were also similar but with different frequencies. Additionally, the sequence of regorafenib followed by fruquintinib showed longer overall survival.
CLINICAL COLORECTAL CANCER
(2022)
Article
Oncology
Elisa Conde, Julie Earl, Lorena Crespo-Toro, Carolina Blanco-Agudo, Edurne Ramos-Munoz, E. Macarena Rodriguez-Serrano, Jose Carlos Martinez avila, Laura Salinas-Munoz, Silvia Serrano-Huertas, Reyes Ferreiro, Mercedes Rodriguez-Garrote, Bruno Sainz, Bartomeu Massuti, Pilar Garcia Alfonso, Manuel Benavides, Enrique Aranda, Maria Laura Garcia-Bermejo, Alfredo Carrato
Summary: This study validated a range of serum miRNAs, SNPs, and Notch 1 expression as predictive biomarkers associated with response or toxicity to regorafenib therapy in colorectal cancer patients, offering potential for personalized treatment strategies in fragile patients with CRC.
Article
Oncology
Emaan Haque, Ibrahim N. Muhsen, Abdullah Esmail, Godsfavour Umoru, Charisma Mylavarapu, Veronica B. Ajewole, Maen Abdelrahim
Summary: This study retrospectively reviewed the data of metastatic colorectal cancer patients who received combination therapy of regorafenib and fluorouracil. The results showed that this treatment option could provide disease control for some patients without new adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
E. Eraslan, M. Dogan, F. Yildiz, A. Ilhan, O. B. Oksuzoglu
Summary: In patients with metastatic colorectal cancer who failed on regorafenib treatment, rechallenge chemotherapy demonstrated a significant survival benefit compared to best supportive care, particularly in patients with a better Eastern Cooperative Oncology Group Performance Status (ECOG PS).
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Summary: This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC. Results showed that this combination therapy was feasible and produced a high response rate of 72% in Chinese patients with MSS mCRC, with generally tolerable and manageable toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jean-Philippe Metges, Dominique Genet, David Tougeron, Catherine Ligeza, Michel Ducreux, Christophe Borg, Rosine Guimbaud, Jean-Marc Phelip, Louis-Marie Dourthe, Stefano Kim
Summary: The real-world evidence from the French cohort of the CORRELATE study demonstrates that regorafenib is a safe and effective treatment option for metastatic colorectal cancer, aligning with findings from Phase III clinical trials and the global CORRELATE population.
Article
Oncology
Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: The study found that regorafenib treatment can cause hypertension and identified the risk factors associated with severe hypertension. Pre-existing primary hypertension and previous anti-VEGF treatment for >= 700 days were found to be independent risk factors for the development of hypertension.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Biochemistry & Molecular Biology
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Summary: This retrospective study examined the clinical characteristics and efficacy of FTD/TPI in patients with metastatic colorectal cancer. The results showed that FTD/TPI is effective as a third-line treatment, regardless of mutational status and tumor sidedness, by prolonging progression-free survival and overall survival.
Article
Oncology
Shun Ishiyama, Takeshi Yamada, Masato Nakamura, Masanobu Enomoto, Kiichi Sugimoto, Hajime Yokomizo, Chihiro Kosugi, Ryo Ohta, Kei Ishimaru, Hiromichi Sonoda, Keiichiro Ishibashi, Hidekazu Kuramochi, Yoichiro Yoshida, Daisuke Ichikawa, Keiji Hirata, Hiroshi Yoshida, Yojiro Hashiguchi, Hideyuki Ishida, Keiji Koda, Kenji Katsumata, Kazuhiro Sakamoto
Summary: The study demonstrated that dose-escalation therapy of regorafenib is well tolerated for Japanese patients, with improved survival rates and low incidence of adverse events.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Feng-E Jiang, Hui-Juan Zhang, Cai-Yan Yu, Ai-Na Liu
Summary: This study investigated the efficacy and safety of regorafenib or fruquintinib combined with camrelizumab in treating patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer. The combination therapy showed promising efficacy with manageable toxicity, and common adverse events included RCCEP, fatigue, hypertension, hand-foot skin reaction, and thyroid dysfunction.
Review
Oncology
Satoru Iwasa, Toshihiro Kudo, Daisuke Takahari, Hiroki Hara, Ken Kato, Taroh Satoh
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Masahito Kotaka, Shigeyoshi Iwamoto, Hironaga Satake, Daisuke Sakai, Toshihiro Kudo, Mutsumi Fukunaga, Ken Konishi, Yoshihito Ide, Taro Ikumoto, Akihito Tsuji, Yasushi Sano, Takeshi Kato, Naotoshi Sugimoto, Taroh Satoh, Akiyoshi Kanazawa, Takayasu Kurata, Takeharu Yamanaka, Naohiro Tomita
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Yukinori Kurokawa, Jin Matsuyama, Kazuhiro Nishikawa, Atsushi Takeno, Yutaka Kimura, Kazumasa Fujitani, Ryohei Kawabata, Yoichi Makari, Tetsuji Terazawa, Hisato Kawakami, Daisuke Sakai, Toshio Shimokawa, Taroh Satoh
Summary: In this study comparing the efficacy and toxicities of docetaxel plus S-1 (DS) and cisplatin plus S-1 (CS) regimens for AGC without measurable lesions, DS showed slightly but non-significantly less toxicity and higher efficacy in terms of overall survival compared to CS.
Article
Surgery
Yoko Hiraki, Yutaka Kimura, Motohiro Imano, Hiroaki Kato, Mitsuru Iwama, Osamu Shiraishi, Atsushi Yasuda, Masayuki Shinkai, Tomoki Makino, Masaaki Motoori, Makoto Yamasaki, Hiroshi Miyata, Takao Satou, Taroh Satoh, Hiroshi Furukawa, Masahiko Yano, Yuichiro Doki, Takushi Yasuda
Summary: The study aimed to determine the clinical significance of micrometastases after neoadjuvant chemotherapy and the difference in controlling micrometastases using different regimens in resectable advanced esophageal squamous cell carcinoma. The results indicated that controlling micrometastases in the lymph nodes varied by regimen and may be associated with preventing ESCC recurrence.
Article
Oncology
Yasushi Murachi, Daisuke Sakai, Jun Koseki, Chiaki Inagaki, Naohiro Nishida, Toshifumi Yamaguchi, Taroh Satoh
Summary: This study retrospectively reviewed the medical records of patients treated with regorafenib between 2013 and 2019, finding that sarcopenia is a significant negative predictor for overall survival in these patients. Patients receiving a total regorafenib dose of < 3360 mg or a relative dose intensity of less than 75% also experienced shorter survival times.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Shingo Noura, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh
Summary: Lessons learned from this study indicate that panitumumab monotherapy is effective and feasible for frail or elderly patients with RAS wild-type unresectable colorectal cancer, especially for left-sided tumors. It could be considered as an additional therapeutic option for those who are not suitable for intensive chemotherapy.
Article
Oncology
Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, Shu-Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric van Cutsem, Maria Alsina, Zhu Alexander Cao, Jia Lu, Pooja Bhagia, Chie-Schin Shih, Yelena Y. Janjigian
Summary: Current treatment options for patients with HER2-positive advanced gastric cancer are limited, with poor prognosis. Pembrolizumab in combination with trastuzumab and chemotherapy may provide a benefit for these patients.
Article
Oncology
Chiaki Inagaki, Daichi Maeda, Kazue Hatake, Yuki Sato, Kae Hashimoto, Daisuke Sakai, Shinichi Yachida, Norio Nonomura, Taroh Satoh
Summary: Next-generation sequencing (NGS) assay is widely utilized in clinical practice in Japan due to its reimbursement by the country's universal health-care system for cancer patients who have completed standard treatment. However, reimbursement is limited to a specific patient population, making it challenging for some patients to benefit from the NGS assay results. Early performance of NGS assay and broader reimbursement are necessary to maximize the clinical benefit and delivery of precision oncology. Access to clinical trials and disclosure of presumed germline findings can also impact patient outcomes.
Article
Oncology
Ryohei Yukimoto, Naohiro Nishida, Tsuyoshi Hata, Shiki Fujino, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Taroh Satoh, Yamamoto Hirofumi, Tsunekazu Mizushima, Yuichiro Doki, Hidetoshi Eguchi
Summary: The study identified a unique metabolic gene profile in BRAF V600E-mutated tumors, with high expression of enolase 2 (ENO2) and enhanced dependency on it. Knockdown of ENO2 inhibited proliferation and migration of cancer cells, and increased sensitivity to BRAF V600E inhibitor. Inhibition of ENO2 also suppressed MAPK and PI3K/Akt signaling pathways, suggesting an additional oncogenic role of ENO2 in CRC progression.
Article
Oncology
Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino
Summary: ctDNA sequencing is more effective in detecting FGFR2 amplification in patients with advanced gastric cancer compared to tissue analysis, and these patients may respond to FGFR inhibitors.
CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Hiromichi Sato, Kazuki Sasaki, Tomoaki Hara, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Mirei Ogita, Shogo Kobayashi, Eric di Luccio, Takaaki Hirotsu, Yuichiro Doki, Hidetoshi Eguchi, Taroh Satoh, Shizuka Uchida, Hideshi Ishii
Summary: This article describes the causes and complexity of pancreatic ductal adenocarcinoma (PDAC), emphasizing the importance of early diagnosis and the multifaceted characteristics of PDAC in terms of cancer cell metabolism, mesenchymal cells, and metagenomics. The article also mentions various pathway alterations associated with PDAC treatment refractoriness and prospects for the application of new technologies.
Article
Oncology
Hisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya, Takaki Yoshikawa, Junichi Sakamoto, Taroh Satoh
Summary: There is no clear preference between S-1 and capecitabine in combination with platinum agent as first-line therapy for patients with HER2-negative unresectable advanced or recurrent gastric cancer. However, S-1 plus cisplatin (SP) achieves deeper tumor shrinkage than capecitabine plus cisplatin (XP) in differentiated gastric cancer, leading to longer overall survival. In undifferentiated gastric cancer, SP consistently showed better clinical results than XP.
Article
Oncology
Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, Manabu Shiozawa, Hisateru Yasui, Taito Esaki, Yoshinori Kagawa, Tadamichi Denda, Taroh Satoh, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Masahiro Goto, Satoshi Yuki, Tomohiro Nishina, Eiji Oki, Eiji Shinozaki, Nobuhisa Matsuhashi, Naoki Takahashi, Akihito Tsuji, Koushiro Ohtsubo, Masashi Wakabayashi, Takashi Ikeno, Masayuki Hata, Justin Odegaard, Takayuki Yoshino
Summary: The relationship between metastatic site and ctDNA detection was investigated in patients with limited-extent metastatic colorectal cancer (mCRC). The results showed that the metastatic site had an impact on ctDNA detection.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Masanori Terashima, Masaki Aizawa, Manabu Ohashi, Ryo Tanaka, Tatsuya Yamada, Takahiro Kinoshita, Hisayuki Matsushita, Koshiro Ishiyama, Kei Hosoda, Yasuhiro Yuasa, Shusuke Haruta, Naoki Kakihara, Kazuhiro Nishikawa, Gen Yunome, Taroh Satoh, Takeo Fukagawa, Hitoshi Katai, Narikazu Boku
Summary: This study investigated the efficacy of preoperative chemotherapy as initial treatment in GC patients with CY1 and/or P1a. Results showed that preoperative chemotherapy did not provide a survival benefit for GC patients with CY1 and/or P1a, but showed favorable survival in patients who converted to P0 and CY0.
Meeting Abstract
Oncology
Hyun Cheol Chung, Yung-Jue Bang, Charles S. Fuchs, Shukui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric Van Cutsem, Maria Alsina, Z. Alexander Cao, Xinqun Chen, Pooja Bhagia, Chie-Schin Shih, Yelena Yuriy Janjigian
JOURNAL OF CLINICAL ONCOLOGY
(2020)